The aim of this study was to evaluate tissue and steroid receptor heterogeneity in endometrial carcinoma specimens as a possible source of discordance between biochemically assayed receptor status and response to endocrine treatment. For this purpose the oestrogen receptor (OR) and progesterone receptor (PR) levels in specimens from 16 endometrial carcinoma patients were analysed on adjacent tissue sections using both a radiochemical and an immunohistochemical assay. With immunohistochemical receptor analysis extensive tissue and tumour cell receptor heterogeneity was observed. Many tumour samples revealed up to 75 per cent contamination with benign tissue. In the majority of cases, evaluation of immunoreactivity in normal tissue elements of the specimen could explain the apparent discordance between semiquantitative immunohistochemical receptor scoring of tumour cells and radiochemical receptor assay. Immunohistochemical analysis of OR and PR in endometrial carcinoma specimens allows a more specific determination of tumour cell receptor content and hence may yield a more accurate prediction of response to endocrine therapy than the biochemical assay.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/path.1711610207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of optimal secondary cytoreductive surgery on survival outcomes in women with recurrent endometrial carcinoma: A systematic review and meta-analysis.
Int J Gynaecol Obstet
January 2025
Department of Medicine, University of Udine, Udine, Italy.
Background: Management of recurrent endometrial carcinoma (EC) represents a challenge. Although a complete resection of visible disease at secondary surgery (R0) is recommended, the impact of R0 on survival outcomes is unclear and pooled data are lacking.
Objective: To quantitatively assess the impact of R0 on survival outcomes in women with EC recurrence.
Prognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.
Histopathology
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Aims: Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes.
View Article and Find Full Text PDFGut microbiota and endometrial cancer: research progress on the pathogenesis and application.
Ann Med
December 2025
Department of Gynecology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
As one of the three major malignant tumors in women, the morbidity of endometrial cancer is second only to that of cervical cancer and is increasing yearly. Its etiological mechanism is not clear, and the risk factors are numerous and common and are closely related to obesity, hypertension, diabetes, etc. The gut microbiota has many strains, which play a considerable part in normal digestion and absorption in the human body and the regulation of the immune response.
View Article and Find Full Text PDFBurden of cancer attributable to sedentary behaviour in Germany: an epidemiological analysis of survey data.
BMJ Open
January 2025
Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
Objectives: Sedentary behaviour (SB) is associated with increased risks of breast, colorectal, endometrial, ovarian and rectal cancers. However, the number of cancer cases attributable to SB in Germany and the associated costs are unknown.
Setting: Numbers and proportions (population-attributable fractions, PAF) of new cancer cases attributable to SB with published risk estimates for Germany for the years 2024, 2030 and 2040.
Causal effect of C-reaction protein and endometrial cancer: Genetic evidence of the role of inflammation in endometrial cancer.
Medicine (Baltimore)
November 2024
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Consensus remains elusive regarding the relationship between C-reactive protein (CRP) levels and endometrial cancer (EC). Our study sought to elucidate the causal association between CRP and EC, aiming to contribute to the understanding of this complex interplay. We primarily utilized the random-effects inverse variance-weighted method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!